Key result
NZ-58 enhances cardiac NaV1.5 channel function through closed-state binding but slows recovery from inactivation.
Answers are grounded in this paper and cite their sources.
NZ-58 demonstrates unique interactions with voltage-gated channels, suggesting potential as a lead compound for therapeutic ion channel modulation despite its non-selectivity.
1.5, but its recovery from inactivation was slowed. NZ-58 was able to bind to the channels in the closed state, not requiring the activated conformation of the VSDs, and it could exert its effects when applied from either side of the membrane. Being non-selective, NZ-58 is not an ideal lead compound for therapeutic ion channel modulation. However, considering that many clinically used ion channel modulators are multi-target "dirty drugs" that still achieve therapeutic benefit, and the unique features of its interactions with voltage-gated channels, we suggest that NZ-58 is worthy of further investigations as a prospective ion channel modulator lead compound.
No takes yet. Share an insight, caveat, or question.
Domingos et al. (2026) studied this question. NZ-58 was evaluated. NZ-58 enhanced the function of the cardiac NaV1.5 channel by binding in the closed state, though its recovery from inactivation was slowed.
Synapse has enriched 10 related papers. Consider them for comparative context: